Navigation Links
AcelRx to Present at the Lazard 6th Annual Healthcare Conference
Date:11/13/2009

REDWOOD CITY, Calif., Nov. 13 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced that Thomas Schreck, President & Chief Executive Officer, and Pamela Palmer, MD, PhD, Chief Medical Officer, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference to be held November 17-18, 2009, at The St. Regis Hotel, New York.

AcelRx Pharmaceuticals' presentation is scheduled for Wednesday, November 18, at 3:15 PM Eastern Time.

Mr. Schreck and Dr. Palmer will be providing an update on three market-driven AcelRx products: ARX-01, Sufentanil NanoTab PCA System, a proprietary drug/device product which offers a non-invasive alternative to intravenous patient-controlled analgesia (IV PCA) for the management of acute post-operative pain in patients requiring opioid analgesia during hospitalization; ARX-02, Sufentanil NanoTab Breakthrough Pain Management System for treatment of cancer pain, a proprietary sublingual dosage form of sufentanil; and ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet need for a non-invasive product to provide mild sedation, anxiolysis and analgesia with rapid onset of action for painful and anxiety-producing office-based surgical procedures.

AcelRx has reported positive Phase 2 results from three studies with ARX-01 and successfully completed an End-of-Phase 2 meeting with the FDA in late October, 2009.

Mr. Schreck will discuss anticipated Company milestones for the remainder of 2009 and those expected to occur in 2010.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of currently approved compounds. For additional information about AcelRx Pharmaceuticals visit http://www.acelrx.com.

SOURCE AcelRx Pharmaceuticals, Inc.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
4. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
5. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
6. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
7. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
8. West to Present at Investor Conference
9. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10. John Madden to Honor the NFLs Best Offensive Linemen with Madden Most Valuable Protectors Award Presented by Prilosec OTC(R)
11. Chimerix to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
Breaking Medicine Technology:
(Date:4/28/2017)... Pensacola, FL (PRWEB) , ... April 28, 2017 ... ... Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data ... ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home care ... Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its blog ... and read organized content on topics such as home care (generally) as well as ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to create ... by the continuing support of the Jane and Leonard Korman Family Foundation. The ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American ... 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious list ... Vice President Walter Mondale, actor Michael J. Fox and former U.S. Attorney General ...
(Date:4/27/2017)... ... , ... Offering the purest product of its kind, Swissx Labs AG has ... than the market has seen before. Swissx uses proprietary strains of hemp plants grown ... process for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. ...
Breaking Medicine News(10 mins):